These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17392622)

  • 1. HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.
    Zou W; Berglund L
    Prev Cardiol; 2007; 10(2):96-103; quiz 104-5. PubMed ID: 17392622
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
    Kotler DP
    J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients.
    Barbaro G; Klatt EC
    Curr Pharm Des; 2003; 9(18):1475-81. PubMed ID: 12769727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxic metabolic syndrome associated with HAART.
    Haugaard SB
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):429-45. PubMed ID: 16863444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.
    Umeh OC; Currier JS
    Curr HIV/AIDS Rep; 2005 Aug; 2(3):132-9. PubMed ID: 16091260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
    Willig AL; Overton ET
    Curr HIV/AIDS Rep; 2016 Oct; 13(5):289-96. PubMed ID: 27541600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe dyslipidemia and immune activation in HIV patients with dysglycemia.
    Jin C; Ji S; Xie T; Höxtermann S; Fuchs W; Lu X; Wu H; Cheng L; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    HIV Clin Trials; 2016 Sep; 17(5):189-96. PubMed ID: 27409415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular dysfunction in human immunodeficiency virus infection.
    Cade WT
    J Cardiometab Syndr; 2008; 3(2):83-7. PubMed ID: 18453807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic abnormalities among HIV-infected patients: a current review.
    Kibirige D; Ssekitoleko R
    Int J STD AIDS; 2013 Aug; 24(8):603-11. PubMed ID: 23970578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary heart disease in people infected with HIV.
    Malvestutto CD; Aberg JA
    Cleve Clin J Med; 2010 Aug; 77(8):547-56. PubMed ID: 20682517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
    Dorey-Stein Z; Amorosa VK; Kostman JR; Lo Re V; Shannon RP
    J Cardiometab Syndr; 2008; 3(2):111-4. PubMed ID: 18453812
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
    Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral therapy and coronary heart disease: the need for perspective.
    Egger M; Junghans C; Friis-Møller N; Lundgren JD
    AIDS; 2001; 15 Suppl 5():S193-201. PubMed ID: 11816168
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertension, HIV infection, and highly active antiretroviral therapy].
    Bernardino de la Serna JI; Zamora FX; Montes ML; García-Puig J; Arribas JR
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):32-7. PubMed ID: 19409669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.